BioMed Research International

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation


Status
Published

Lead Editor

1Vascular Medicine/Hemostasis Center, University Hospital Frankfurt, 60590 Frankfurt, Germany

2Department of Pharmacy, Namur Research Institute for Life Sciences (NARLIS), University of Namur, 5000 Namur, Belgium

3Department of Medicine, Lenox Hill Hospital, 100 East 77th Street, New York, NY 10075, USA


Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation

Description

A variety of direct oral anticoagulants (DOA) targeting specific coagulation parameters have already entered the market. Moreover, new indications for the already available drugs will be released each year over the next few years. The benefit of DOA has succeeded in overcoming the limitations of conventional anticoagulants. However, the long-term safety of DOA is not as well known as the treatment with heparins or coumarin derivates. There is also a lack of knowledge about serious drug interactions with DOA. The risk of bleeding in special patient cohorts has not been sufficiently examined. At present, there is no antidote for DOA available for human use. Due to the heterogeneous mode of action and pharmacokinetic profile, each DOA will vary in its effects on laboratory assays, and to avoid mismanagement clinicians are placed in a difficult position.

Knowledge and understanding of these conditions have led to a huge number of investigations to provide a better handling with DOA. We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts in the development of strategies and technologies to improve the treatment with DOA. Potential topics include, but are not limited to:

  • Development of test methods for monitoring the novel anticoagulants
  • Elucidating the role of risk factors in the development of adverse effects under DOA treatment
  • Development of strategies to treat adverse effects and to reverse anticoagulant effects
  • Management of DOA in the peri- and postoperative setting
  • Development of new modalities for clinical characterization of treatment with DOA
  • Advances in molecular genetics and diagnostics to give new insights into the mechanism of DOA using animal and human models
  • Identification of new targets for DOA
  • Identifying new biomarkers/correlates for the outcome measurement of DOA

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/hematology/diron/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2015
  • - Article ID 549803
  • - Editorial

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation

Helen Mani | Jonathan Douxfils | Jack Ansell
  • Special Issue
  • - Volume 2015
  • - Article ID 345138
  • - Review Article

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations

Jonathan Douxfils | Helen Mani | ... | François Mullier
  • Special Issue
  • - Volume 2015
  • - Article ID 876923
  • - Research Article

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

Martin Krejczy | Job Harenberg | ... | Gregory Y. H. Lip
  • Special Issue
  • - Volume 2015
  • - Article ID 630482
  • - Research Article

Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action

Qudsia Rashid | Mohammad Abid | ... | Mohamad Aman Jairajpuri
  • Special Issue
  • - Volume 2014
  • - Article ID 385014
  • - Review Article

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting

Anne-Sophie Dincq | Sarah Lessire | ... | François Mullier
  • Special Issue
  • - Volume 2014
  • - Article ID 583794
  • - Review Article

Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates

Lisa M. Baumann Kreuziger | Joseph C. Keenan | ... | David J. Dries
  • Special Issue
  • - Volume 2014
  • - Article ID 567026
  • - Clinical Study

Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients

Alicia DeFelipe-Mimbrera | Araceli Alonso Cánovas | ... | Jaime Masjuan
  • Special Issue
  • - Volume 2014
  • - Article ID 616405
  • - Review Article

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants

Lessire Sarah | Dincq Anne-Sophie | ... | Mullier François
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit